Elizabeth Bhatt
Director/Board Member presso EFFECTOR THERAPEUTICS, INC.
Patrimonio netto: 5 195 $ in data 31/03/2024
Profilo
Elizabeth P.
Bhatt is an Independent Director at eFFECTOR Therapeutics, Inc. and the Chief Operating Officer at Septerna, Inc. She previously served as an Independent Director at Locust Walk Acquisition Corp., Vice President-Corporate Development at Gilead Sciences, Inc., and Chief Operating & Business Officer at Achaogen, Inc. She also held the position of Chief Business & Strategy Officer at Applied Molecular Transport, Inc. Bhatt received her undergraduate degree from Pomona College, her graduate degree from the University of California San Diego, and her MBA from Kellogg School of Management.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
29/02/2024 | 361 ( 0.01% ) | 5 195 $ | 31/03/2024 |
Posizioni attive di Elizabeth Bhatt
Società | Posizione | Inizio |
---|---|---|
EFFECTOR THERAPEUTICS, INC. | Director/Board Member | 25/08/2021 |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Chief Operating Officer | 28/07/2022 |
Precedenti posizioni note di Elizabeth Bhatt
Società | Posizione | Fine |
---|---|---|
ACHAOGEN | Chief Operating Officer | 30/06/2019 |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/09/2017 |
EFFECTOR THERAPEUTICS, INC. | Director/Board Member | - |
APPLIED MOLECULAR TRANSPORT INC. | Corporate Officer/Principal | - |
Formazione di Elizabeth Bhatt
Pomona College | Undergraduate Degree |
University of California San Diego | Graduate Degree |
Kellogg School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
APPLIED MOLECULAR TRANSPORT INC. | Health Technology |
EFFECTOR THERAPEUTICS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Locust Walk Acquisition Corp.
Locust Walk Acquisition Corp. Financial ConglomeratesFinance Locust Walk Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on October 2, 2020 and is headquartered in Boston, MA. | Finance |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Health Technology |
- Borsa valori
- Insiders
- Elizabeth Bhatt